Tagged with VAT

Europe Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in how the EU values innovation is now, calling for pricing system reform, speedier regulatory and HTA procedures, manufacturing investments, and…

China Suzhou’s bioBAY has emerged as one of China’s most dynamic biotechnology clusters, bringing together hundreds of biotech and medtech companies within an ecosystem designed to support the full innovation cycle, from early discovery to global partnerships. In this conversation, CEO Michael Yin reflects on how the park has evolved alongside…

Taiwan Sabrina Zimmerman, General Manager for Taiwan, Hong Kong, and Macau and APAC (excluding Japan) Portfolio Head at Biogen, shares her perspective on the company’s expanding presence in Asia and its evolving focus beyond neuroscience. She discusses the region’s innovation potential, the strategic priorities driving rare disease and other exciting therapeutic…

Hong Kong Sabrina Chan, Senior Executive at HKAPI, highlights progress in Hong Kong’s biomedical ambitions, including establishing an independent regulator, expanding clinical trial capacity via the Greater Bay Area Clinical Trial Institute (GBAICTI), and leveraging 34 years of real-world health data. She underscores efforts to enhance primary healthcare, support rare disease access,…

Taiwan Boston Scientific’s Dan Silver reflects on his global leadership journey and the evolution of the company’s presence in one of Asia’s most advanced healthcare systems. Silver discusses Boston Scientific’s growth drivers, Taiwan’s strategic role in Asia-Pacific, and striking the balance between innovation, digital health, and value-based care. He also shares…

Taiwan Jack Chiu is leading Siemens Healthineers’ transformation from equipment supplier to value-based healthcare partner in Taiwan. Under the 2026–2030 “Elevating” strategy, Taiwan serves as an Asia-Pacific innovation landing pad, validating advanced imaging and AI solutions. With market leadership in high-end MRI, CT, and hybrid ORs, Chiu is focusing on precision…

Taiwan Dr Ethan Shen moves comfortably between the clinic, the laboratory, and capital markets, and this conversation reflects that rare vantage point. He explains how YD Bio is built not as a single-asset biotech, but as an integrated platform designed to connect diagnostics, data, and advanced therapies with real clinical execution.…

France France finally has a full budget for 2026, ending months of stasis, and providing a degree of certainty to industry. However, especially for pharma, continual price cuts threaten the sustainability of France as an investment destination, although the reindustrialisation incentives contained with the ‘France 2030’ plan are leading to an…

USA As rare disease science accelerates, regulators face growing pressure to adapt without compromising rigour. In this interview, Amy Comstock Rick explains how the FDA Rare Disease Innovation Hub is strengthening cross-centre coordination, evolving evidence expectations for ultra-rare conditions, and creating new spaces for dialogue between regulators, developers, and patients. The…

Taiwan Epidemiologist Dr Chen Chien-jen has spent decades at the intersection of scientific research and public health policy. His pioneering work on arsenic-induced health hazards informed international water safety standards, whilst his leadership during the SARS outbreak established Taiwan’s pandemic preparedness infrastructure. In this wide-ranging conversation, Dr Chen discusses Taiwan’s approach…

USA Genome editing is moving from proof of concept to clinical reality, but questions around scale, cost, and responsibility now define its future. In this interview, Brad Ringeisen outlines how the Innovative Genomics Institute is shaping CRISPR as a platform for real-world impact, bridging philanthropy, academia, and industry while navigating regulation,…

Taiwan Frederic Kuo, founder and CEO of Fethiann, established the company in 2017 within Taiwan’s Hsinchu Science Park. With a PhD background and extensive experience in new drug development, Frederick has positioned Fethiann as Taiwan’s sole specialist in natural phytochemical active pharmaceuticals. The company’s unique business model integrates Active Phytochemicals Ingredient…